Calendario›UTHR›Treprostinil · PRN
Treprostinil · PRN
Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
Ensayo de UNITED THERAPEUTICS Corp en Hipertension arterial pulmonar.
Más ensayos de: Hipertensión arterial pulmonar.
- Fase
- no aplica
- Estado
- Completado
- Participantes
- 43
- Centros
- 10
- Fin del objetivo primario
- sep 2019
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en abr 2019.
Qué mide
Change From Baseline in Patient Global Impression of Severity (PGI-S) Score in Cohort A Participants at Approximately 30 Minutes of Previous Dose of Inhaled Treprostinil (the Expected Peak Level) on Day 1 (Baseline, Approximately 30 m of previous dose of inhaled treprostinil (the expected peak level) on Day 1) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis is an observational, multicenter, single-day, Phase 2 study. This study will include a 14-day Screening Period and Study Day 1 clinic visit. Participants will be required to perform an activity to induce symptoms of PAH, and participants' severity of self-reported symptoms of PAH will be measured from pre-activity, immediately after the activity, and through the 30-minute recovery. Participants will be asked about their PAH symptoms using 3 PGI-S questions that address their overall PAH symptoms, shortness of breath, and physical fatigue.
Más ensayos de UTHR
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Parenteral Treprostinil · ARTISAN | Fase 4 | En marcha, sin reclutar | abr 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Ralinepag | Fase 3 | Reclutando por invitación | dic 2026 (prevista) |
| Oral treprostinil · ADAPT | no aplica | En marcha, sin reclutar | mar 2027 (prevista) |
| Inhaled Treprostinil | Fase 3 | Reclutando pacientes | nov 2027 (prevista) |
| 10 GE Xenokidney · EXPAND | Fase 1/2 | Reclutando pacientes | oct 2028 (prevista) |
| GGTA1 KO Thymokidney · EXTEND | Fase 1/2 | Reclutando pacientes | nov 2029 (prevista) |
Todos los de UTHR, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT03888365), actualizada en feb 2021.